A significant number of patients taking Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL) develop atrial fibrillation (AF).

Recent novel treatments for chronic lymphocytic leukemia (CLL), such as second-generation covalent Bruton tyrosine kinase inhibitors (cBTKis) and venetoclax-obinutuzumab (VenO), may offer better ...

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic ...

Detailed price information for Sellas Life Sciences Group Inc (SLS-Q) from The Globe and Mail including charting and trades.

A study has demonstrated the potential of a novel ligand-based CAR T-cell therapy for targeting CD7-positive T-cell malignancies, including T-cell acute lymphoblastic leukemia (T-ALL) and T-cell ...

Cash: As of March 31, 2025, Cellectis had $246 million in consolidated cash, cash equivalents, restricted cash and fixed-term deposits classified as current-financial assets. The Company believes its ...

The blood cancer market is experiencing robust growth, driven by rising incidence rates and advancements in targeted therapies and immuno-oncology. I ...

This piece is not just for those who might wish to write a book, it also can be generalized to other ... And then I did a PhD to do with acute lymphoblastic leukemia at the University of Melbourne. I ...

Actinium Pharmaceuticals, Inc. (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that the first patient was enrolled on the trial studying Iomab-ACT ...

The global leukemia therapeutics market is poised for substantial growth in the coming decade, driven by advances in treatment technologies, increasing awareness of target-specific therapies, and the ...

But that’s the reality of cancer. Specifically, acute lymphocytic leukemia (ALL). ALL results when a cancerous growth causes immature lymphocytes — a certain type of white blood cells — to ...

offering a novel approach to overcoming tumor heterogeneity while sparing healthy cells. A phase 1 trial evaluating SENTI-202 demonstrated positive preliminary results in treating relapsed/refractory ...